Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      • Home
      • Farhat Nasim

      Articles By : Farhat Nasim

      Lupin gets USFDA nod for generic Clobazam Tablets

      Lupin gets USFDA nod for generic Clobazam Tablets

      Farhat Nasim18 Dec 2018 12:29 PM IST
      New Delhi: Pharma major Lupin recently announced that it has received approval for its Clobazam Tablets, 10 mg and 20 mg from the United States Food...
      Junshi Biosciences raises $394 million after pricing IPO at bottom of range

      Junshi Biosciences raises $394 million after pricing IPO at bottom of range

      Farhat Nasim18 Dec 2018 9:00 AM IST
      HONG KONG: Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering...
      J&J announces $5 billion share repurchase after shares extend losses

      J&J announces $5 billion share repurchase after shares extend losses

      Farhat Nasim18 Dec 2018 8:59 AM IST
      The share repurchase was just the latest effort the healthcare conglomerate has made to boost investor confidence.New Delhi: Johnson & Johnson...
      Madras High Court refuses to set aside stay on online sale of drugs

      Madras High Court refuses to set aside stay on online sale of drugs

      Farhat Nasim17 Dec 2018 9:40 AM IST
      Chennai: The Madras High Court recently refused to set aside the stay order given by it on the issue of the online sale of drugs. It also directed the...
      USFDA completes Biocon Telangana plant inspection,no observations issued

      USFDA completes Biocon Telangana plant inspection,no observations issued

      Farhat Nasim17 Dec 2018 6:00 AM IST
      New Delhi: Biotechnology major Biocon Monday said the US health regulator has completed the inspection of its Telangana manufacturing facility without...
      Under Tax Scrutiny: Can GST be levied on Implants and Medical Devices

      Under Tax Scrutiny: Can GST be levied on Implants and Medical Devices

      Farhat Nasim16 Dec 2018 12:13 PM IST
      New Delhi: An impending challenge for the hospitals is foreseen with the tax department scrutinizing the applicability of Goods and Services Tax (GST)...
      Minister notifies Parliament: Precautions to curb unsafe medical syringes in the market

      Minister notifies Parliament: Precautions to curb unsafe medical syringes in the market

      Farhat Nasim16 Dec 2018 10:05 AM IST
      New Delhi: Responding to a query raised in Rajya Sabha, Ministry of Health and Family Welfare informed the parliament about the precautions taken by...
      Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease

      Rusan Pharma gets DCGI nod to APOSAN for treating Parkinsons Disease

      Farhat Nasim16 Dec 2018 9:31 AM IST
      Rusan Pharma said it has developed the drug, which would be available in the form of injections, pen and continuous infusion pumps, indigenously and...
      Court: OxyContin makers must release the secret testimony

      Court: OxyContin makers must release the secret testimony

      Farhat Nasim16 Dec 2018 9:15 AM IST
      A three-judge panel ruled Friday the deposition of Richard Sackler must be unsealed, along with about 17 million pages of other documents that were...
      Alembic Pharma raises Rs 350 crore via NCDs

      Alembic Pharma raises Rs 350 crore via NCDs

      Farhat Nasim16 Dec 2018 9:00 AM IST
      “The NCD committee of Alembic Pharma…Has allotted 1,500, 9 per cent rated unsecured listed redeemable non-convertible debentures (NCDs)… Aggregating...
      Major Setback to Fortis: SC stops sale process to IHH

      Major Setback to Fortis: SC stops sale process to IHH

      Farhat Nasim15 Dec 2018 11:40 AM IST
      The Japanese firm, which has filed the contempt plea against the Singh brothers in the apex court, has said that it was promised some shares of Fortis...
      Relief: HC junks Centres ban on private firms selling OXYTOCIN

      Relief: HC junks Centre's ban on private firms selling OXYTOCIN

      Farhat Nasim15 Dec 2018 10:30 AM IST
      Oxytocin is also administered to pregnant women to "prevent and treat" postpartum haemorrhage (PPH). PPH accounts for about 35 per cent of all...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok